O'Loughlin Steve 4
4 · Actinium Pharmaceuticals, Inc. · Filed Dec 29, 2023
Insider Transaction Report
Form 4
O'Loughlin Steve
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-12-28+253,123→ 253,123 totalExercise: $5.00Exp: 2033-12-28→ Common Stock (253,123 underlying)
Footnotes (2)
- [F1]This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant.
- [F2]Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested.